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Abstract 
Background: Criteria for the 2007 WHO algorithm for diagnosing tuberculosis among HIV-infected seriously ill 
patients are the presence of one or more danger signs (respiratory rate > 30/min, heart rate > 120/min, tempera-
ture > 39 °C, and being unable to walk unaided) and cough ≥ 14 days. Determining predictors of poor outcomes 
among HIV-infected inpatients presenting with WHO danger signs could result in improved treatment and diagnostic 
algorithms.
Methods: We conducted a prospective cohort study of inpatients presenting with any duration of cough and WHO 
danger signs to two regional hospitals in Cape Town, South Africa. The primary outcome was all-cause mortality up to 
56 days post-discharge, and the secondary outcome a composite of any one of: hospital admission for > 7 days, died 
in hospital, transfer to a tertiary level or tuberculosis hospital. We first assessed the WHO danger signs as predictors of 
poor outcomes, then assessed the added value of other variables selected a priori for their ability to predict mortality 
in common respiratory opportunistic infections (CD4 count, body mass index (BMI), being on antiretroviral therapy 
(ART), hypotension, and confusion) by comparing the receiver operating characteristic (ROC) area under the curve 
(AUC) of the two multivariate models.
Results: 484 participants were enrolled, median age 36, 66% women, 53% had tuberculosis confirmed on culture. 
The 56-day mortality was 13.2%. Inability to walk unaided, low BMI, low CD4 count, and being on ART were inde-
pendently associated with poor outcomes. The multivariate model of the WHO danger signs showed a ROC AUC of 
0.649 (95% CI 0.582–0.717) for predicting 56-day mortality, which improved to ROC AUC of 0.740 (95% CI 0.681–0.800; 
p = 0.004 for comparison between the two ROC AUCs) with the multivariate model including the a priori selected 
variables. Findings were similar in sub-analyses of participants with culture-positive tuberculosis and with cough dura-
tion ≥ 14 days.
Conclusion: The study design prevented a rigorous evaluation of the prognostic value of the WHO danger signs. Our 
prognostic model could result in improved algorithms, but needs to be validated.
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Background
Undiagnosed tuberculosis is a major cause of death 
among hospitalised HIV-infected patients in Africa [1, 
2]. The World Health Organization (WHO) recommen-
dations to improve the diagnosis of tuberculosis and 
facilitate rapid initiation of empiric anti-tuberculosis 
treatment among adults in high HIV prevalence settings 
include an algorithm for seriously ill patients present-
ing with cough and one or more of the following danger 
signs: respiratory rate >  30/min, heart rate >  120/min, 
temperature > 39  °C, and being unable to walk unaided 
[3]. Developing a strong evidence base for predictors of 
poor outcomes in seriously ill inpatients could result in 
improved treatment and diagnostic algorithms. Empiric 
antituberculosis treatment improved 8-week survival of 
inpatients with WHO danger signs and negative sputum 
smears, but had no effect on survival in inpatients with-
out danger signs in a Ugandan study; [4] which indicates 
that the danger signs have prognostic value.
We were unable to find any studies that evaluated pre-
dictors of poor outcomes in the WHO algorithm for seri-
ously ill patients. Many studies have evaluated predictors 
of mortality of the three commonest respiratory oppor-
tunistic infections in HIV-infected patients: Pneumocys-
tis jirovecii pneumonia (PJP), bacterial pneumonia, and 
tuberculosis. Most reports of prognostic indicators for 
PJP include laboratory tests, pulmonary function tests, 
and/or sophisticated imaging that are not widely avail-
able in resource-limited settings. Simple predictors of 
mortality in PJP include wasting, hypoxia, hypotension, 
and lymphopenia [5, 6]. The pneumonia severity index 
performs well at predicting mortality among hospital-
ized HIV-infected patients with bacterial pneumonia, but 
it has multiple clinical, laboratory and radiological fea-
tures [7–9]. CRB-65 is a simple clinical pneumonia sever-
ity score, which predicted mortality and hospital stay in 
patients irrespective of HIV status in one study, [9] but 
predicted mortality poorly in a Malawian study, which 
found that male sex, wasting, non-ambulatory functional 
status, extremes of temperature, and hypotension pre-
dicted mortality [10]. Most of the studies that assessed 
predictors of mortality in patients with HIV-associated 
tuberculosis were conducted before the availability of 
antiretroviral therapy (ART) and focused on 6  month 
mortality, and thus are not informative about predicting 
short-term mortality in inpatients with newly diagnosed 
tuberculosis in the ART era. A Ugandan study of hospi-
talized HIV-infected patients presenting with suspected 
pneumonia of 2  weeks to 6  months duration, most of 
whom had tuberculosis, found heart rate >  120/min, 
respiratory rate > 30/min, oxygen saturation < 90%, and 
CD4 cell count < 50 cells/µL predicted mortality [11].
We assessed the WHO danger signs together with 
other prognostic variables selected for their ability to 
predict mortality in HIV-associated respiratory illness 
(confusion, hypotension, CD4 count, ART status) as pre-
dictors of mortality and poor outcomes in participants 
fulfilling entry criteria for the WHO algorithm for seri-
ously ill HIV-infected patients with a cough enrolled 
into a prospective cohort study in Cape Town, South 
Africa. We enrolled participants with cough of any dura-
tion, rather than the WHO recommendation of 2 weeks 
or more, because studies in high burden countries have 
shown that acute presentations of pulmonary tubercu-
losis occur commonly in HIV-infected patients [12, 13]. 
We have previously reported the development of clinical 
prediction rules and the use of Xpert MTB/RIF assay to 
improve the diagnosis of tuberculosis in this cohort [14].
Methods
Study population
We conducted a prospective cohort study. The study sites 
were two regional hospitals serving communities with 
a high burden of HIV and tuberculosis in Cape Town, 
South Africa: GF Jooste Hospital from November 2011 to 
February 2013, when the hospital closed; and Khayelitsha 
District Hospital from March 2013 until October 2014. 
Inclusion criteria were: known or newly diagnosed HIV 
infection, within 24 h of hospital admission, ≥ 18 years of 
age, cough of any duration, and at least one of the WHO 
danger signs. Exclusion criteria were: being on anti-
tuberculosis therapy, having completed anti-tuberculosis 
therapy in the previous month, defaulting anti-tubercu-
losis therapy within the past 6 months, exacerbations of 
congestive cardiac failure or chronic obstructive pulmo-
nary disease, and inability to produce a spontaneous or 
induced sputum sample. After discharge from hospital, 
participants were followed up at 28 and 56 days. Follow 
up was either a physical visit to hospital or a telephonic 
consult to assess their clinical response and outcome. 
During the study period the CD4 criterion for ART ini-
tiation was < 350 cells/uL.
Data collection
Participants enrolled into the study received a standard-
ized work-up to assess the aetiology of their respiratory 
illness. A standard case record form was used for captur-
ing demographic data, medical history, symptoms, and 
signs on clinical examination. All participants had a chest 
radiograph on admission. CD4 counts were done on 
admission unless a result was available within 6 months 
prior to admission. Sputum samples were taken from 
all participants: 1 sample for Gram stain, culture and 
sensitivity; and 2 samples for smear examination with 
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auramine staining for acid-fast bacilli (AFB) and myco-
bacterial culture. On 1 sample sent for mycobacterial cul-
ture the Cepheid Xpert MTB/RIF assay was performed. 
If participants were unable to produce sputum spontane-
ously, sputum induction was performed using an ultra-
sonic nebulizer and hypertonic saline. Participants had 
blood taken for a mycobacterial blood culture (BacT/
Alert® specimen bottle).
Study definitions
The case definition of tuberculosis was a positive tuber-
culosis culture from any site. Anti-tuberculosis therapy 
was commenced in participants who met microbiological 
criteria (any one of: positive auramine stain for AFB, pos-
itive Cepheid Xpert MTB/RIF assay, positive culture for 
tuberculosis); and/or radiological criteria (a chest radio-
graph showing either mediastinal and/or hilar lymph 
nodes or miliary infiltrates; an abdominal ultrasound 
showing multiple enlarged lymph nodes and/or multiple 
splenic hypoechoic lesions and/or a pericardial effusion); 
and/or or pleural effusions/ascites showing a lympho-
cytic exudate. Anti-tuberculosis therapy was also com-
menced if participants showed no clinical improvement 
after 3–5 days of antibiotic therapy.
The diagnosis of bacterial pneumonia was made clini-
cally with consistent symptoms and evidence of pulmo-
nary consolidation on a chest x-ray. Participants clinically 
diagnosed with bacterial pneumonia were started on 
empirical antibiotic therapy with a ß-lactam antibiotic 
(usually intravenous ceftriaxone). A macrolide was added 
if participants fulfilled the criteria for severe pneumonia 
(CRB-65 score > 2) [15].
PJP was diagnosed if the following were present: cough 
duration ≤  12  weeks, bilateral interstitial infiltrates on 
chest radiograph, and hypoxia at rest or on exertion 
(> 5% drop in oxygen saturation). Weight based high dose 
trimethoprim-sulfamethoxazole and corticosteroid ther-
apy were initiated in these participants.
Statistical analysis
The primary outcome was all-cause mortality from 
admission to 56 days post-discharge. The secondary out-
come was a composite of any one of: hospital admission 
for > 7 days, died in hospital, transfer to a tertiary level 
hospital, or transfer to a tuberculosis hospital. In Cape 
Town patients with tuberculosis are only admitted to 
tuberculosis hospitals if they are too ill for ambulatory 
care (unless they have extensively drug-resistant tuber-
culosis), therefore admission to a tuberculosis hospital 
reflects need for prolonged hospitalisation.
Analyses were performed using STATA 12.1 (Stata-
Corp, Texas, USA). Missing data were imputed using 
chained equations and five iterations. We checked the 
results of the imputation by comparing a complete case 
analysis with the imputation set.
Multivariate logistic regression analysis was performed 
including variables in the multivariate models selected 
a priori for their ability to predict mortality in common 
respiratory opportunistic infections and their imple-
mentability in resource-limited settings. We first investi-
gated the primary outcome of all-cause mortality within 
the 56  days of follow-up post-discharge. We tested two 
multivariate models for this outcome: the WHO multi-
variate model (variables were the WHO danger signs); 
and the augmented multivariate model (variables were 
the WHO danger signs, and the following: CD4 count, 
body mass index (BMI), being on ART, hypotension (sys-
tolic blood pressure < 90 mmHg or diastolic blood pres-
sure ≤ 60 mmHg), and confusion). We compared the area 
under the curve (AUC) for the receiver-operating charac-
teristic (ROC) of the two models. We then investigated 
the composite secondary outcome in a similar manner. 
A sub-analysis on all participants with culture positive 
tuberculosis was performed using the same approach for 
each of the specified outcomes.
Results
Participant characteristics
Two thousand and fifty-four patients were screened for 
inclusion into the study; 484of whom met the inclusion 
criteria and were enrolled (Fig.  1). The baseline char-
acteristics of the participants are listed in Table  1. The 
majority of participants had  >  1 WHO danger sign at 
Fig. 1 Flow diagram for participant inclusion into the study
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presentation; 23% (111/484) had one, 45% (216/484) had 
two, 27% (133/484) had three, and 5% (24/484) had all 
four danger signs. The diagnoses and outcomes of par-
ticipants are summarised in Table  2. Sixty-four percent 
(309/484) of participants were started on anti-tuber-
culosis therapy, of whom 255 (83%) were confirmed on 
culture. Simultaneous tuberculosis and bacterial pneu-
monia was diagnosed in 26% (125/484) of participants 
and simultaneous tuberculosis and PJP was diagnosed in 
4% (21/484) of participants.
Primary outcome
The WHO multivariate model showed that being unable 
to walk unaided was the only WHO danger sign that was 
independently associated with death at 56 days post-dis-
charge (Table  3). A sub-analysis limited to participants 
with cough duration of ≥  14  days (which is the WHO 
algorithm inclusion criterion) showed similar findings. 
The augmented multivariate model showed that the fol-
lowing variables were independently associated with 
death at 56 days post-discharge: a lower CD4 count, being 
on ART, and being unable to walk unaided (Table  3). 
Twenty-seven of 59 (46%) participants who died within 
56 days post-discharge were on ART; 8 had been on ART 
for less than 3 months (5 of whom had a CD4 count < 50 
cells/µL), and 9 were failing ART with a viral load (VL) of 
>  1000 RNA copies/mL. The WHO multivariate model 
showed a ROC AUC of 0.649 (95% CI 0.582–0.717) for 
predicting death at 56  days post-discharge. The aug-
mented multivariate model showed an improved ROC 
AUC of 0.740 (95% CI 0.681–0.800; p =  0.004 for com-
parison between the two ROC AUCs) (Fig. 2a).
A sub-analysis of the primary outcome among Myco-
bacterium tuberculosis culture-positive patients, showed 
that none of the WHO danger signs independently pre-
dicted death at 56 days post-discharge (Additional file 1: 
Table S1). In the augmented multivariate model, death 
at 56  days post-discharge was independently associ-
ated with a lower CD4 count and being on ART (Addi-
tional file 1: Table S2). Thirty-four of the 59 participants 
who died were culture-positive for M. tuberculosis, 14 
of whom where on ART: 7 were on ART for less than 
3  months (5 of whom had a CD4 count <  50 cells/µL), 
and 4 were failing ART with a viral load (VL) of > 1000 
RNA copies/mL. In this sub-analysis of culture con-
firmed tuberculosis the WHO model showed a ROC 
AUC of 0.604 (95% CI 0.503–0.705) for predicting death 
at 56 days post-discharge. The augmented model showed 
an improved ROC AUC of 0.748 (95% CI 0.665–0.831; 
p = 0.009 for comparison between the two ROC AUCs) 
(Fig. 2b). Study hospital was not significantly associated 
with the primary outcome.
Secondary outcome
The WHO multivariate model showed that being unable 
to walk unaided was the only danger sign that was inde-
pendently associated with the secondary outcome (any 
one of the following: hospital admission for >  7  days, 
death in hospital, transfer to a tertiary level hospital, or 
transfer to a tuberculosis hospital) (Table  4). The aug-
mented multivariate model showed that the secondary 
outcome was independently predicted by a lower CD4 
count, a lower BMI, and being unable to walk unaided 
(Table 4). The WHO multivariate model showed a ROC 
Table 1 Baseline characteristics of 484 participants 
with cough and one or more of the WHO danger signs
a 17 missing values
b 1 missing values
c 2 missing values
d Systolic blood pressure < 90 mmHg or diastolic blood pressure ≤ 60 mmHg
Baseline variables
 Age Median (IQR) 36 (30 to 42)
 Sex (female) n (%) 317 (66)
 BMI (kg/m2) Median (IQR)a 20 (18 to 39)
 CD4 (cells/µL) Median (IQR)b 89 (34 to 210)
 Cough duration Median days (IQR)c 14 (7 to 21)
 Cough duration < 14 days n (%) 186 (39)
 Hypotensived n (%) 119 (25)
 Using ART n (%) 171 (35)
 Duration on ART (years) Median (IQR) 2.3 (0.2 to 5)
 Confused n (%) 88 (18)
WHO danger signs
 Respiratory rate > 30 n (%) 315 (65)
 Heart rate > 120 n (%) 383 (79)
 Temp > 39 °C n (%) 81 (17)
 Unable to walk unaided n (%) 259 (54)
Table 2 Diagnoses and hospitalization outcomes of 484 
participants with cough and the WHO danger signs
a Total number of diagnoses > 100% due to coinfections
Diagnosesa
 Tuberculosis n (%) 255 (53)
 Community acquired pneumonia n (%) 245 (51)
 Pneumocystis jirovecii pneumonia n (%) 51 (11)
 Other n (%) 41 (8)
Hospitalization and discharge
 Days in hospital Median (IQR) 5 (3 to 7)
 Discharged alive n (%) 386 (80)
 Transfer to tertiary hospital n (%) 22 (5)
 Transfer to tuberculosis hospital n (%) 53 (11)
 Lost to follow-up n (%) 37 (8)
Mortality
 Died in hospital n (%) 23 (5)
 Died during follow up n (%) 36 (8)
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AUC of 0.686 (95% CI 0.639–0.734) for predicting the 
secondary outcome. The augmented multivariate model 
showed an improved ROC AUC of 0.718 (95% CI 0.673–
0.764; p =  0.001 for comparison between the two ROC 
AUCs) (Additional file 1: Figure S1A).
A sub-analysis of the WHO multivariate model among 
culture-positive tuberculosis participants, showed that 
being unable to walk unaided was the only WHO dan-
ger sign that independently predicted the secondary 
outcome (Additional file  1: Table S2). The augmented 
multivariate model showed that the secondary outcome 
was independently predicted by a lower CD4 count, 
a lower BMI, and being unable to walk unaided (Addi-
tional file  1: Table S2). The WHO multivariate model 
showed a ROC AUC of 0.697 (95% CI 0.631–0.763) for 
predicting the secondary outcome. The augmented mul-
tivariate model showed an improved ROC AUC of 0.750 
(95% CI 0.68–0.813; p = 0.017 for comparison between 
the two ROC AUCs) (Additional file  1: Figure S1B). 
Study hospital was not significantly associated with the 
secondary outcome.
Discussion
We found that being unable to walk unaided was the 
only WHO danger sign that predicted poor outcomes 
in a cohort of seriously ill HIV-infected participants 
hospitalised with cough. We established that several of 
the potential predictors of poor outcomes we selected a 
priori (lower BMI, lower CD4 count, and being on ART) 
improved the ability to predict poor outcomes. The high 
prevalence of tuberculosis in our cohort enabled us to 
also assess prognostic predictors in participants with 
culture-positive tuberculosis, with similar findings. To 
our knowledge ours is the first study to have evaluated 
the prognostic ability of the WHO danger signs, as well 
as other potential predictors, in the population of interest 
Table 3 WHO multivariate model (variables were WHO danger signs) and augmented multivariate model (variables 
were the WHO danger signs, and the following: CD4 count, body mass index, being on ART, hypotension, and confusion) 
for predicting death at 56 days post-discharge. Imputation set used due to missing CD4 and BMI data
a Adjusted odds ratio
b Increase in increments of 100 cells/µL
c Increase per 1 kg/m2
d Systolic blood pressure < 90 mmHg or diastolic blood pressure ≤ 60 mmHg
Variable WHO multivariate model Augmented multivariate model
Category aORa 95% confidence interval Wald’s p value aOR 95% confidence interval Wald’s p value
Respiratory rate > 30
 No Referent group Referent group
 Yes 1.25 0.68 to 2.29 0.469 1.05 0.55–2.02 0.879
Heart rate > 120
 No Referent group Referent group
 Yes 0.68 0.36 to 1.29 0.240 0.59 0.29–1.19 0.138
Temperature > 39 °C
 No Referent group Referent group
 Yes 0.66 0.28 to 1.52 0.329 0.67 0.28–1.59 0.364
Unable to walk
 No Referent group Referent group
 Yes 2.94 1.58 to 5.47 0.001 2.06 1.06–3.99 0.032
CD4 cells/µLb 0.62 0.45–0.86 0.004
BMI (kg/m2)c 1.02 0.96–1.08 0.535
On ART at admission
 No Referent group
 Yes 2.54 1.37–4.72 0.003
Hypotensived
 No Referent group
 Yes 1.10 0.55–2.23 0.782
Confused
 No Referent group
 Yes 1.48 0.71–3.06 0.295
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Fig. 2 Comparison of area under the curve (AUC) for the receiver operating characteristic (ROC) for the WHO multivariate model (variables were 
WHO danger signs) and the augmented multivariate model (variables were the WHO danger signs, and the following: CD4 count, body mass index, 
being on ART, hypotension, and confusion) for predicting death at 56 days post-discharge in all participants (a) and in participants with culture-
positive tuberculosis (b)
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and in the sub-group with a final diagnosis of tubercu-
losis. In 2016 WHO updated the seriously ill algorithm 
to include the Xpert MTB/RIF assay and cough of any 
duration, [16] which makes our findings applicable to the 
updated algorithm, but cough is no longer a requirement.
The strong associations we found between being una-
ble to walk unaided and the primary and secondary out-
comes in our cohort indicate that this WHO danger sign 
is a simple, objective prognostic marker. The association 
between poor outcomes and both low CD4 counts and 
BMI was expected, as these are well-established prognos-
tic markers in HIV infection [11, 17–20]. However, we 
expected that tachypnoea, confusion, and hypotension 
would be significant predictors of poor prognosis, given 
that these have been shown to be of prognostic value in 
patients with a variety of HIV-associated pulmonary 
infections [10, 11, 18, 21, 22].
Among the culture-positive tuberculosis participants, 
being unable to walk unaided, low BMI, low CD4 count, 
and being on ART remained strong prognostic indicators 
of poor outcomes. Most studies that assessed predictors 
of mortality among HIV-infected tuberculosis partici-
pants have been retrospective observational cohorts and 
evaluated outcomes at 6 months. We could not find any 
studies of inpatients that assessed predictors of 56-day 
mortality or poor outcome. Some of the independent 
predictors of poor outcomes in patients with HIV-associ-
ated tuberculosis from other studies include: age, [20, 23] 
sex, [20] ambulatory status, [24] WHO clinical stage 4, 
[23] BMI, [19] lower CD4 count, [20, 23, 24, 19, 25] ART, 
[20, 24, 25] cotrimoxazole prophylactic therapy, [24] hae-
moglobin, [19] and white cell count [19, 25].
Being on ART independently predicted death at 
56  days post-discharge in the whole cohort, as well as 
Table 4 WHO multivariate model (variables were WHO danger signs) and augmented multivariate model (variables 
were the WHO danger signs, and the following: CD4 count, body mass index, being on ART, hypotension, and confusion) 
for predicting the secondary outcome (any one of: hospital admission for > 7 days, death in hospital, transfer to a tertiary 
level hospital, or transfer to a tuberculosis hospital)
Imputation set used due to missing CD4 and BMI data
a Adjusted odds ratio
b Increase in increments of 100 cells/µl
c Increase per 1 kg/m2
d Systolic blood pressure < 90 mmHg or diastolic blood pressure ≤ 60 mmHg
Variable WHO multivariate model Augmented multivariate model
Category aORa 95% confidence interval Wald’s p value aOR 95% confidence interval Wald’s p value
Respiratory rate > 30
 No Referent group Referent group
 Yes 1.19 0.79 to 1.79 0.408 1.21 0.79–1.85 0.376
Heart rate > 120
 No Referent group Referent group
 Yes 0.96 0.60 to 1.55 0.883 0.93 0.57–1.52 0.722
Temperature > 39 °C
 No Referent group Referent group
 Yes 1.01 0.60 to 1.68 0.980 0.97 0.57–1.64 0.899
Unable to walk
 No Referent group Referent group
 Yes 4.48 3.05 to 6.57 < 0.001 3.96 2.66–5.90 < 0.001
CD4 cells/µLb 0.85 0.73–0.98 0.025
BMI (kg/m2)c 0.97 0.93–1.00 0.073
On ART at admission
 No Referent group
 Yes 1.28 0.84–1.96 0.249
Hypotensived
 No Referent group
 Yes 0.95 0.60–1.52 0.838
Confused
 No Referent group
 Yes 1.48 0.87–2.53 0.146
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among culture positive tuberculosis participants, which 
was an unexpected finding. Two studies reported a 
similar result to our findings, with increased mortality 
among patients who started ART within 3  months [26] 
and 6  months, [27] respectively, prior to their tubercu-
losis diagnosis. The increased mortality seen in patients 
started on ART a few months prior to the diagnosis of 
tuberculosis, as was the case in 8/27 of our participants 
on ART who died within 56 days post-discharge, could be 
due to the development of unmasking immune reconsti-
tution inflammatory syndrome, which has been associ-
ated with an increased mortality [28]. Nine of nineteen 
participants who died within 56 days post-discharge and 
who were on ART for > 3 months had virologic failure, 
which is associated with an increased mortality [29]. 
Finally, patients with virologic failure typically have poor 
adherence, and their increased mortality in our study 
could in part be related to poor health-seeking behaviour 
and delayed presentation.
Our study has several limitations. First, we were una-
ble to determine the cause of death in our participants. 
Second, all our participants had one or more WHO dan-
ger signs, and the lack of a control group without dan-
ger signs limited our ability to determine the prognostic 
value of the danger signs. Third, we did not have defini-
tive reference standards to diagnose bacterial pneumonia 
and PJP. Finally, our cohort was from a setting with high 
prevalence of both HIV and tuberculosis. Our findings 
may not be generalizable to areas with lower incidence of 
tuberculosis or to children.
In conclusion, we assessed prognostic indicators of res-
piratory illness in our prospective cohort of HIV-infected 
participants presenting with a cough of any duration 
and WHO danger signs. We established that being una-
ble to walk unaided, low BMI, and low CD4 count were 
strong predictors of morbidity and mortality. These find-
ings were similar among culture-positive tuberculosis 
patients. The increased mortality we observed in par-
ticipants on ART is an important determinant to keep 
in mind when assessing acute respiratory illness in HIV-
infected patients. Future research should focus on filling 
these gaps and validating our results in different study 
populations.
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